Outcome of Board Meeting held on May 27, 2026.

Rossari Biotech's Board of Directors met on May 27, 2026 and approved two key items. First, the Board recommended re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of 3 years (October 21, 2026 to October 20, 2029), subject to shareholder approval. Ms. Esha has 33 years of finance experience, having held senior roles at Glenmark Pharmaceuticals and Bajaj. Second, the Board approved grant of 830,050 stock options under the Rossari Employee Stock Option Plan - 2019, convertible into an equal number of equity shares at an exercise price of Rs. 537 per option. The options vest over 4 years with 20% each in years 1-3 and 40% in year 4.